Nasdaq

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

NEW YORK, April 15, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs, today ...
Nasdaq

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 ...
Seeking Alpha

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, ...
Seeking Alpha

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer ...

- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two ...